Subscriber access provided by Radboud University Nijmegen
Article
Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design Karl Drlica, Arkady Mustaev, Tyrell R Towle, Gan Luan, Robert J. Kerns, and James M Berger ACS Chem. Biol., Just Accepted Manuscript • DOI: 10.1021/cb500629k • Publication Date (Web): 13 Oct 2014 Downloaded from http://pubs.acs.org on October 14, 2014
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
ACS Chemical Biology is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
1 2 3 4 5
Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design Karl Drlica‡*, Arkady Mustaev‡, Tyrell R. Towle¶, Gan Luan‡, Robert J. Kerns¶*, and James M. Berger#§*
6 7
‡
8
New Jersey Medical School, Rutgers Biomedical and Health Sciences, 225 Warren St.,
9
Newark, NJ 07103
Public Health Research Institute and Department of Microbiology & Molecular Genetics,
10 11
¶
12
Sciences & Experimental Therapeutics, University of Iowa College of Pharmacy, 115 S.
13
Grand Ave., Iowa City, IA 52246
14
#
15
University of California, Berkeley, CA 94720
16
§
17
of Medicine, 725 N. Wolfe St., Baltimore, MD 21205
Division of Medicinal & Natural Products Chemistry, Department of Pharmaceutical
Molecular and Cell Biology Department, Quantitative Biosciences Institute, Stanley Hall,
Present address: Biophysics and Biophysical Chemistry, Johns Hopkins University School
18 19
* To whom correspondence should be addressed. (Karl Drlica [Tel 917 821 6847; Fax 973
20
854 3101, Email
[email protected]]; Robert J. Kerns [Tel 319 335 8800, Fax 319-
21
335-8766, Email
[email protected]]; James M. Berger [Tel: 410-955-7163; Fax: 410-
22
955-0637; Email:
[email protected]]), Drs. Drlica, Kerns, and Berger contributed equally
23
to experimental design, obtaining funding, and manuscript preparation.
24
4
25
School of Medicine, 725 N. Wolfe St., Baltimore MD 21205
Present address: Department of Biophysics and Biophysical Chemistry, The Johns Hopkins
26 27
Short title: Bypassing quinolone resistance with diones
28 29
Keywords: E. coli, moxifloxacin, cleaved complexes, docking, dione
30
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
31
ABSTRACT
32
Widespread fluoroquinolone resistance has drawn attention to quinazolinediones (diones),
33
fluoroquinolone-like topoisomerase poisons that are unaffected by common quinolone-
34
resistance mutations. To better understand differences between quinolones and diones, we
35
examined their impact on the formation of cleaved complexes (drug-topoisomerase-DNA
36
complexes in which the DNA moiety is broken) with gyrase, one of two bacterial targets of
37
the drugs. Formation of cleaved complexes, measured by linearization of a circular DNA
38
substrate, required lower concentrations of quinolone than dione. The reverse reaction,
39
detected as resealing of DNA breaks in cleaved complexes, required higher temperatures and
40
EDTA concentrations for quinolones than diones. The greater stability of quinolone-
41
containing complexes was attributed to the unique ability of the quinolone C3/C4 keto acid to
42
complex with magnesium and form a previously-described drug-magnesium-water bridge
43
with GyrA-Ser83 and GyrA-Asp87. A nearby substitution in GyrA (G81C) reduced activity
44
differences between quinolone and dione, indicating that resistance due to this variation
45
derives from perturbation of the magnesium-water bridge. To increase dione activity, we
46
examined a relatively small, flexible C-7-3-(aminomethyl)pyrrolidinyl substituent, which is
47
distal to the bridging C3/C4 keto acid substituent of quinolones. The 3-
48
(aminomethyl)pyrrolidinyl group at position C-7 was capable of forming binding interactions
49
with GyrB-Glu466, as indicated by inspection of crystal structures, computer-aided docking,
50
and measurement of cleaved-complex formation with mutant and wild-type GyrB proteins.
51
Thus, modification of dione C-7 substituents constitutes a strategy for obtaining compounds
52
active against common quinolone-resistant mutants.
53 54 55
ACS Paragon Plus Environment
Page 2 of 33
Page 3 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
56 57
INTRODUCTION
58 59
Fluoroquinolones are important antimicrobials that trap two bacterial topoisomerases, gyrase
60
and topoisomerase IV, on DNA as complexes in which the DNA is broken. The complexes,
61
commonly called cleaved complexes,1, 2 are the primary lesions responsible for quinolone
62
activity.3-5 The DNA ends in cleaved complexes are constrained by covalent linkage to the
63
topoisomerase, which facilitates resealing of the DNA breaks after drug removal.
64
Consequently, damage caused by the complexes, such as inhibition of DNA synthesis, is
65
reversible when drug is removed.6 Reversibility may be clinically important, since treatment
66
of infections often involves fluctuating drug concentrations that may drop low enough to
67
allow resealing of cleaved DNA. Resealing may reduce quinolone efficacy and increase
68
pathogen survival. Pathogen survival can also arise from expansion of resistant
69
subpopulations containing topoisomerase mutations that reduce drug binding and thereby
70
cleaved-complex formation. Thus, understanding how the structure of quinolone-class
71
antimicrobials affects topoisomerase-mediated DNA cleavage and resealing is central to
72
designing more effective drug candidates.
73
Cleaved-complex formation can be assayed by incubating gyrase or topoisomerase IV
74
with quinolone and circular DNA, followed by treatment with an ionic detergent, such as
75
sodium dodecyl sulfate (SDS), to dissociate the complexes. Gel electrophoresis is then used
76
to separate the DNA species; the appearance of linear DNA indicates complex formation.7, 8
77
Reversal of complex formation is observed as DNA resealing, i.e., the disappearance of
78
linear DNA arising prior to dissociation of the complex with SDS. Reversal conditions,
79
which involve destabilization of drug-bound enzyme-DNA complexes, include: i) dilution,9 ii)
80
incubation at high temperature,9 or iii) treatment with ethylenediamine tetraacetic acid
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
81
(EDTA).7, 10 EDTA chelates polyvalent metal ions, and its action can be explained by
82
participation of Mg2+ in quinolone binding. Indeed, X-ray crystallographic studies of drug-
83
enzyme-DNA complexes reveal that the C3/C4 keto acid moiety of fluoroquinolones
84
coordinates a Mg2+ ion and forms a previously described drug-magnesium-water bridge to
85
amino acid residues in helix-4 of either GyrA (gyrase) or ParC (topoisomerase IV).11-14
86
Additional magnesium coordination occurs within the topoisomerase active site,15 making it
87
likely that multiple magnesium ions participate in cleaved-complex formation and reversal.
88
Drug-mediated magnesium coordination has been characterized by comparison of
89
fluoroquinolones and quinazolinediones (diones), quinolone-like compounds (Figure 1A)
90
that lack the carboxylate group needed for magnesium coordination with drug.9, 11, 16-18
91
Diones are potentially important clinically, because they exhibit striking activity against
92
several types of fluoroquinolone-resistant mutant containing amino acid substitutions in
93
gyrase and DNA topoisomerase IV.17, 19-21 For two of these substitution sites (equivalent to
94
GyrA-83 and GyrA-87 in E. coli), an absence of drug-mediated magnesium coordination has
95
been implicated in the biochemical behavior of diones.9, 16, 18 A third resistance site (GyrA-
96
81) is not expected to directly participate in metal-ion coordination, but a GyrA-G81C
97
resistance substitution has been proposed to interfere with ion binding indirectly by sterically
98
perturbing the geometry of the gyrase acidic group at a distance.20 Such interference has not
99
been examined biochemically. A consequence of the stabilizing magnesium bridge is that
100
fluoroquinolones exhibit greater activity than diones with wild-type enzyme and cells.18, 19, 21
101
Thus, a challenge is to find ways to stabilize dione-containing cleaved complexes, thereby
102
increasing activity of an agent that may bypass existing resistance.
103
The present work began with a set of C-8-methoxy diones active against
104
fluoroquinolone-resistant bacterial mutants.19, 20 To better understand differences between
105
diones and quinolones, we examined their effects on gyrase-mediated DNA breakage and
ACS Paragon Plus Environment
Page 4 of 33
Page 5 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
106
resealing using EDTA, thermal treatments, and a GyrA-G81C substitution. We then sought
107
ways to both stabilize dione-containing cleaved complexes and increase dione activity. A 3-
108
(aminomethyl)pyrrolidinyl substituent (hereafter called an aminomethyl pyrrolidine group) at
109
position C-7 afforded increased activity for both dione and fluoroquinolone derivatives.
110
Investigation of extant X-ray structures, along with docking studies, revealed a potential
111
interaction between GyrB-Glu466 and the aminomethyl pyrrolidine group that might account
112
for increased activity through a slightly altered binding orientation. In accord with this
113
observation, a GyrB-E466C substitution preferentially decreased dione activity, supporting a
114
stabilizing role for the GyrB interaction with the C-7 aminomethyl pyrrolidine group.
115
Overall, the work establishes the functional relevance of crystal structures of cleaved
116
complexes, explains the action of the GyrA-G81C resistance substitution, addresses
117
crossover activity of diones for human topoisomerase II, and provides a new approach for
118
bypassing the protective activity of current quinolone-resistance mutations.
119 120
121
RESULTS AND DISCUSSION Cleaved-complex formation with quinolone and dione pairs. Quinazolinediones and
122
cognate fluoroquinolones having four different C-7 ring moieties (Figure 1A) were incubated
123
at various concentrations with E. coli gyrase and plasmid DNA to form cleaved complexes
124
that were assayed by the appearance of linear DNA (see Supplementary Figure S1 for an
125
example of electrophoretic separation of plasmid species). For each compound pair, the
126
quinolone was 10-100 times more active than the dione, as judged by the concentration
127
required to linearize ~20% of the DNA (Figure 1B). These results parallel earlier studies
128
with cultured bacterial cells.19, 20 The UING5-249/UING5-207 pair was the most active; thus,
129
subsequent work focused on these two compounds.
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
130
DNA resealing stimulated by EDTA differs for dione- and quinolone-containing
131
complexes. Previous studies have shown that type II DNA topoisomerases act through a two-
132
metal mechanism15, 22, 23 and that the metal chelator EDTA helps stimulate resealing of
133
broken DNA in cleaved complexes.1, 2, 10, 17, 24 In an initial experiment, we formed cleaved
134
complexes by incubating gyrase, plasmid DNA, and the fluoroquinolone UING5-249. Then
135
we treated reaction mixtures with EDTA to reseal the DNA. Increasing EDTA concentration
136
caused the recovery of linear DNA to drop, reach a broad minimum beginning at about 2 mM
137
EDTA (the concentration of Mg2+ in the reaction mixture), and then increase (Figure 2A).
138
Addition of Mg2+ after incubation with moderate concentrations of EDTA (2 mM) reversed
139
the resealing stimulated by EDTA (Supplementary Figure S2); incubation with Mg2+ after
140
treatment with a high concentration of EDTA (50 mM) restored resealing (Supplementary
141
Figure S2). Thus, EDTA likely exerts its effects by sequestering Mg2+ ions away from the
142
ternary drug-enzyme-DNA complex.
143
We reasoned that DNA resealing in complexes formed with diones might differ from
144
that of quinolone-containing complexes, because diones cannot participate in magnesium-
145
mediated bridging of drug with GyrA. When we compared cognate dione (UING5-207) and
146
quinolone (UING5-249) for EDTA-dependent effects on DNA resealing, the overall shapes
147
of the curves were similar (Figure 2A). However, in the low EDTA concentration range,
148
reversal of quinolone-mediated DNA cleavage occurred at a higher relative EDTA
149
concentration than observed for the dione. This reduced susceptibility of quinolone-
150
containing complexes to EDTA-mediated DNA resealing is consistent with quinolones
151
having an additional magnesium-dependent interaction that stabilizes their participation in
152
cleaved-complex formation.
153
The response to EDTA concentration may arise from low concentrations of EDTA
154
promoting quinolone dissociation from the complex, thereby shifting gyrase from a DNA-
ACS Paragon Plus Environment
Page 6 of 33
Page 7 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
155
breaking mode to a resealing one; if so, high concentrations of EDTA would then largely
156
eliminate the remaining Mg2+ and thereby disrupt Mg2+-dependent DNA resealing by gyrase.
157
Nicked DNA was recovered at high EDTA concentration (Figure 2B), consistent with these
158
conditions partially inhibiting gyrase-mediated resealing of DNA breaks. Partial resealing
159
associated with high concentrations of EDTA (35 mM) has been observed previously with
160
Streptococcus pneumoniae gyrase-containing complexes.17 However, in that work, 35 mM
161
EDTA failed to induce DNA resealing for an 8-methyl dione complexed with topoisomerase
162
IV.17 The difference at high EDTA concentration seen between the 8-methyl dione and the 8-
163
methoxy derivative used here may derive from tighter binding of the methyl derivative, since
164
formation of cleaved complexes with the methoxy compound requires higher concentrations
165
than its cognate methyl analog.18, 21
166
Since high salt concentration can reverse DNA cleavage induced by some quinolones,17
167
sodium ions present in EDTA solutions could, in principle, contribute to DNA resealing
168
during EDTA treatment. However, we saw no stimulation of DNA resealing by sodium
169
acetate (up to 250 mM, Supplementary Figure S3). Likewise, 200 mM sodium acetate failed
170
to reduce resealing temperature, in contrast to the effects of EDTA treatment (Supplementary
171
Figure S4). Thus, salt effects are probably not responsible for DNA resealing stimulated by
172
low EDTA concentration.
173
A variety of divalent cations, such as Co2+, Ni2+, Pb2+, and Mn2+, can satisfy the
174
requirement for a non-catalytic metal ion in formation of cleaved complexes with both
175
quinolone and dione.9 However, several metal ions, including Ca2+, Cd2+, Zn2+, and Ba2+,
176
also preferentially form complexes with dione-type compounds.9 While the basis for these
177
metal ion differences is not known, the data fit with the idea that in cleaved complexes the
178
metal dependencies of quinolones and diones differ.
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
179
Temperature-promoted DNA resealing differs between dione- and quinolone-
180
containing complexes. In addition to the effects on EDTA-induced resealing, we reasoned
181
that an additional stabilizing magnesium interaction might also increase the reversal
182
temperature of complexes formed with fluoroquinolones relative to cognate diones. When
183
cleaved complexes, formed by incubation of drug, gyrase, and plasmid DNA, were subjected
184
to 5-min incubations at various temperatures, the production of linear DNA showed a distinct
185
decrease over the same temperature range at which supercoiled DNA increased
186
(Supplementary Figure S5; the fraction of nicked DNA grew slightly as temperature
187
increased). For comparison of dione and quinolone, we determined the temperature at which
188
the proportion of linear DNA had decreased by 50%: dione-containing complexes exhibited
189
overall lower DNA resealing temperatures than complexes formed with cognate quinolones
190
(Figure 3A; Supplementary Table S1). In general, compounds having a greater stimulatory
191
effect on DNA cleavage tended to exhibit higher DNA resealing temperature (Figure 3B).
192
The lower thermal stability of cleaved complexes formed with diones was observed over a
193
broad concentration range in which raising dione concentration raised resealing temperature
194
(Supplementary Figure S6). These data suggest that DNA resealing is facilitated by
195
dissociation of quinolone/dione from the complexes. Overall, the results of thermal resealing
196
experiments are consistent with a role for drug-enzyme stability in favoring cleaved-complex
197
formation, a result that accords with the observed stabilizing effects of water-magnesium ion
198
bridging between fluoroquinolones and GyrA/ParC.
199
In previous work, a thermal resealing difference was not observed during comparison
200
of an 8-methyl dione with several commercial quinolones.16 In those experiments complexes
201
were formed with wild-type topoisomerase IV followed by incubation for various times at
202
only a single temperature, 75oC. The present work suggests that 75oC is likely to be above
ACS Paragon Plus Environment
Page 8 of 33
Page 9 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
203
the transition temperature, which could make that particular test insensitive to compound
204
structure.
205
Dione-containing complexes are less sensitive than quinolone-containing complexes
206
to a GyrA-G81C substitution. X-ray analysis of crystal structures for cleaved complexes
207
suggests that drug binding occurs close enough to GyrA-Gly81 for a Cys substitution to
208
sterically perturb quinolone-mediated magnesium bridging.11, 20 Thus, cleaved complexes
209
formed with GyrA-G81C gyrase and quinolones were expected to have properties similar to
210
those of complexes formed with diones. Indeed, when dione UING5-207 and its cognate
211
quinolone (UING5-249) were compared for complex formation with wild-type gyrase, 10- to
212
20-times more dione was required to generate the same amount of linear DNA (Figure 4Ai).
213
By contrast, the difference was only 2-fold when GyrA-G81C was used (Figure 4Aii).
214
Similarly, examination of DNA resealing by GyrA-G81C gyrase at various EDTA
215
concentrations revealed no difference between dione- and fluoroquinolone-containing
216
complexes at low EDTA concentration (Figure 4B) (unlike the result obtained with wild-type
217
gyrase, Figure 2A). The GyrA-G81C substitution also lowered DNA resealing temperature
218
more for the fluoroquinolone than for the dione, bringing them to similar levels (Figure 4C).
219
Overall, these results are consistent with the GyrA-G81C substitution exerting a destabilizing
220
effect on the fluoroquinolone-mediated magnesium linkage that is absent in dione-containing
221
complexes. Thus, the GyrA-G81C substitution joins substitutions at GyrA-83 and GyrA-87
222
in acting by impeding the formation of the quinolone-magnesium-water-enzyme bridge.9, 16
223
Although substitution at GyrA-81 can be strongly protective with cultured cells6, 19, 20
224
and with purified gyrase (Figure 4A), it is seldom associated with clinical resistance,25
225
perhaps due to loss of mutant fitness in human hosts. Interestingly, at high EDTA
226
concentrations, GyrA-G81C gyrase exhibited a reduced ability to reseal dione-containing
227
complexes (Figure 4B). While additional work is required to understand this phenomenon, it
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
228
is likely that GyrA-G81C gyrase may still allow tighter binding of the quinolone than the
229
dione (Fig. 4Aii).
230
C-7 ring substituents interact with GyrB. Comparison of diones having various C-7
231
rings identified UING5-207 as the most active at forming cleaved complexes (Figure 1B).
232
This result is consistent with UING5-207 being more active than other 8-methoxy diones as
233
determined with B. anthracis topoisomerase IV.18 To better understand this elevated activity,
234
we examined published X-ray structures derived from compounds similar to UING5-249 and
235
UING5-207 in complex with type-II topoisomerases and DNA.11-14 When we substituted
236
dione UING5-207 and UING5-249 for moxifloxacin in X-ray structure PDB 2XKK
237
(moxifloxacin complexed with Acinetobacter baumannii topoisomerase IV; a comparable
238
gyrase structure is not presently available), we noticed during manual docking that the
239
primary amine of the C-7 aminomethyl pyrrolidine group is in a position where it could
240
potentially form a salt bridge/hydrogen bond with Glu466 of GyrB (Figure 5A, 5B).
241
Manually rotating the C-7 group of moxifloxacin to make this same binding contact revealed
242
that the secondary amine of the moxifloxacin C-7 group was unlikely to extend far enough to
243
form a similar binding interaction with GyrB Glu466. Thus, the C-7 aminomethyl
244
pyrrolidine substituent appeared to afford an additional binding contact with GyrB.
245
We next turned to computer-aided docking and fitting. The 20 best binding poses for
246
each fluoroquinolone and dione were obtained by first docking with the 2XKK topoisomerase
247
IV crystal structure of cleaved complexes formed with moxifloxacin. The poses were then
248
overlaid and examined for differences in the relative orientations of functional groups and for
249
binding contacts with DNA and protein (see Supplemental Figures S7, S8, and Supplemental
250
Table S2 for the 20 docked poses). Docking of moxifloxacin into the fluoroquinolone-
251
binding site of the 2XKK crystal structure revealed that the C-7 group preferentially adopts a
252
conformation that creates a hydrogen bond to the deoxyribose oxygen of dA-20 (see Figure
ACS Paragon Plus Environment
Page 10 of 33
Page 11 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
253
6A for top-scoring binding pose). In contrast, many of the top binding poses for the UING5-
254
249 fluoroquinolone docked into this site exhibited a 180˚ rotation of the C-7 aminomethyl
255
pyrrolidine group, such that the primary amine of this moiety could form a hydrogen bond
256
with both ParE-Glu437 (corresponding to E. coli GyrB-466) and the backbone carbonyl of
257
nearby ParE-Arg418 (Figure 6B). Indeed, docked poses for UING5-249 revealed that the C-
258
7 aminomethyl pyrrolidine group is capable of simultaneously forming hydrogen bonds with
259
multiple residues. In the rigid C-7 ring system of moxifloxacin, however, the amine group is
260
directly linked to the pyrrolidine and cannot reach ParE-Glu437. A similar difference
261
between binding contacts of the C-7 groups was seen with the cognate diones, UING5-157
262
and UING5-207 (Figure 6C and 6D).
263
In addition to the preferred binding contacts between the primary amine of the
264
aminomethyl pyrrolidine group with ParE-Glu437 (E. coli GyrB-Glu466), the dione UING5-
265
207 also adopted several poses in which the primary amine of the aminomethyl pyrrolidine
266
formed single hydrogen bonding interactions with ParE-Glu437 and the backbone carbonyl
267
of ParE-Arg418 (Figure 6D). An interaction of the moxifloxacin C-7 group with ParE-
268
Arg418 was also observed, but only in a few of the lower-scoring poses (Supplemental Table
269
S2). Thus, the fluoroquinolone and dione derivatives containing a C-7 aminomethyl
270
pyrrolidine appear capable of forming binding interactions with GyrB residues, while the C-7
271
group of moxifloxacin and the cognate dione, UING5-157, preferentially interact with dA-20.
272
As expected from crystal structures, docking the fluoroquinolone required the C-3/C-4
273
ketoacid-magnesium interaction to anchor the fluoroquinolones to helix-4. To observe dione
274
docking, the compounds needed to be anchored through their C-2 carbonyl group to ParC-
275
Arg123, as seen in the PDB 3LTN structure of Streptococcus pneumoniae topoisomerase IV
276
bound to dione and DNA.11
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
277
We next performed docking with the GyrB-E466C substitution by introducing the
278
equivalent change (ParE-E437C) into the 2XKK crystal structure of cleaved complexes
279
formed with A. baumannii topoisomerase IV. With moxifloxacin, the top 20 binding poses
280
were similar to the top 20 binding poses generated using wild-type enzyme (Figure 7A, see
281
Supplementary Figures S7 and S8 for visualization of all 20 binding poses), as expected from
282
moxifloxacin lacking a contact with GyrB-Glu466. Thus, the ParE-E437C (GyrB-E466C)
283
substitution appears to have little effect on the preferred interaction of the C-7 group of
284
moxifloxacin. In contrast, the top 20 binding poses of the fluoroquinolone UING5-249 with
285
the ParE-E437C variant showed greater variation for C-7 group orientation and binding
286
contacts: the primary amine of the C-7 aminomethyl pyrrolidine group formed hydrogen
287
bonds to dA-20, to dT-19, to the backbone carbonyl of ParE-Arg418, or simply failed to form
288
any polar or electrostatic interaction (two DNA contacts are exemplified in Figures 7B and
289
7C). Thus, the Cys substitution severely disrupts interaction with GyrB-466. Similar
290
differences were seen with the cognate diones (Figure 7D and 7E), indicating that the C-7
291
aminomethyl pyrrolidine group might interact with wild-type GyrB and thus provide a
292
stabilizing effect with GyrB that is not seen with the C-7 diazabicylco compounds (i.e.,
293
moxifloxacin and UING5-157). Finally, a consistent observation throughout comparison of
294
the top binding poses was that, as compared to the fluoroquinolone, the positioning and
295
orientation of the dione core structures were highly conserved in all binding poses due to the
296
restriction imposed by the hydrogen bond between the dione C-2 carbonyl group and Arg123
297
of ParC (see overlapping structures in Supplementary Figures S7 and S8).
298
To provide an experimental test for an interaction between the C-7 aminomethyl
299
pyrrolidine group and GyrB-Glu466, we compared cleaved-complex-forming activity of
300
diones UING5-207 and UING5-157 using a GyrB-E466C mutant available from other work.6
301
With wild-type gyrase, UING5-207 was about 10-fold more active than the moxifloxacin-like
ACS Paragon Plus Environment
Page 12 of 33
Page 13 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
302
dione UING5-157 (Figures 8A and 8B). Replacement of the anionic glutamate with the
303
shorter, uncharged cysteine side-chain reduced the activity more for UING5-207 than for
304
UING5-157, presumably due to a loss of C-7 ring interactions between UING5-207 and
305
GyrB-Glu466 (the core portions of diones position similarly in mutant and wild-type protein,
306
Supplementary Figures S7 and S8). The differences shown in Figures 8A, 8B, and 8E are
307
consistent with the GyrB-E466C substitution removing a preferred binding contact for the C-
308
7 aminomethyl pyrrolidine group of dione UING5-207. The unique binding interactions
309
between the aminomethyl pyrrolidine and GyrB thus appears to improve the ability of diones
310
with this substituent to poison gyrases bearing helix-4 substitutions compared to derivatives
311
having other C-7 groups that have been examined to date.
312
The fluoroquinolone comparison (UING5-249 vs. moxifloxacin) with GyrB E466C
313
was more complex, because the substitution could perturb both GyrB-C-7 ring interactions
314
and formation of the magnesium-water bridge at the other end of the fluoroquinolone. When
315
the top 20 poses for each docking run were considered as a whole (Supplementary Figures S7
316
and S8), both moxifloxacin and the UING5-249 fluoroquinolone docked in a generally less-
317
ordered fashion to GyrB-E466C gyrase than to the wild-type enzyme, and the docking
318
orientation around the magnesium ion was less ordered with mutant gyrase. In addition,
319
UING5-249 was unable to form a hydrogen bond to GyrB-466 when it was cysteine. These
320
observations suggest that both fluoroquinolones would exhibit lower activity with GyrB-
321
E466C gyrase and that the reduction for UING5-249 would be slightly greater. Such was the
322
case when cleaved-complex forming activity was measured (Figure 8C, 8D, 8E). Efforts are
323
now being made to obtain crystal structures of cleaved complexes formed with gyrase and
324
either UING5-249 or UING5-207 to confirm and extend conclusions derived from docking
325
and DNA cleavage studies. Dione-resistant mutants are also being examined for the location
326
of GyrB substitutions and impact on drug susceptibility.
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
327
Cross-over activity with human topoisomerase II. For reasons that were previously
328
unclear, the C-7 aminomethyl pyrrolidine group confers crossover activity for
329
fluoroquinolones and diones with human topoisomerase II.18 When we compared spatial
330
orientation of amino acid residues in the cleaved complex region of the crystal structures for
331
A. baumannii topoisomerase IV (2XKK)14 with that of human topoisomerase IIβ (3QX3),26
332
we found that human topoisomerase II has glutamic acid (E522) and arginine (R503) residues
333
in its TOPRIM domain that are conserved with respect to ParE-Glu437 and ParE-Arg418 in
334
topoisomerase IV. While the amino acid sequences adjacent to the glutamate residue
335
(DEVLASQEV and KQIMENAEI in A. baumannii topoisomerase IV and human
336
topoisomerase II, respectively) are not highly conserved, spatial positioning of the glutamate
337
residue relative to DNA and drug binding is highly conserved (3-dimensional conservation).
338
Moreover, the nearby arginine-containing sequences are highly conserved (PIRGKILN vs.
339
PLRGKILN). These similarities suggest that anchoring of the drug to the cleavage site
340
through the conserved binding interaction between the C-7 aminomethyl pyrrolidine group
341
and the TOPRIM domain glutamic acid and/or arginine (as observed with topoisomerase IV,
342
Figures 6B and 6D) contributes to the poisoning activity with helix-4 variants of B. anthracis
343
topoisomerase IV and wild-type human topoisomerase II. Indeed, the binding contacts
344
formed by the C-7 aminomethyl pyrrolidine group that impart activity against helix-4 variants
345
of bacterial type-II topoisomerases are likely to be the same features and contacts that impart
346
C-7 aminomethyl pyrrolidine fluoroquinolone and dione activity against human
347
topoisomerase II.
348
Concluding remarks.
The traditional response to antibiotic resistance has been
349
creation of new compounds to which bacteria are not yet resistant. The present work focused
350
on just such a strategy for quinolone-like quinazolinediones. Judicious choice of C-7 ring
351
substituents, and likely many other substituents yet to be explored, can provide the
ACS Paragon Plus Environment
Page 14 of 33
Page 15 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
352
stabilization needed to generate quinolone-class derivatives that have activity against
353
fluoroquinolone-resistant type II topoisomerases. Diones bypass much of the protective
354
effect of common GyrA-mediated resistance mutations because they do not form the drug-
355
magnesium-water-GyrA bridge characteristic of fluoroquinolones. We found that dione
356
activity can be increased through a specific C-7 ring interaction with E. coli GyrB-466. Since
357
the most active compounds with purified E. coli gyrase were generally the most active with
358
cultured cells (supplementary Table S1), biochemical studies of the type described are likely
359
to be useful for finding more effective agents. In the course of the present work, the Osheroff and Kerns laboratories found that
360 361
quinolone/dione C-7 substituents that facilitate action with bacterial topoisomerase helix-4
362
variants also facilitate action with human topoisomerase II,18 a result explained by the
363
findings reported here. While such activity may cause topoisomerase II-based toxicity in
364
mammalian hosts, other aspects of dione/quinolone structure, such as substituents at the C-8
365
position, can be altered to discriminate activity between human and bacterial enzymes.18 We
366
expect the experimental and computational modeling approach presented above to provide a
367
platform for designing new quinolone-class antibacterials having both elevated activity with
368
wild-type and fluoroquinolone-resistant bacteria, along with reduced activity against human
369
topoisomerase II.
370 371
METHODS GyrA and GyrB subunits of E. coli gyrase, including those with GyrA-G81C and
372 373
GyrB-E466C substitutions, were expressed and purified separately as described previously,6,
374
27
375
Healthcare; gatifloxacin was from Bristol-Meyers-Squibb; PD161148 was from Parke-Davis
376
Division of Pfizer Corp. Other fluoroquinolones and quinazolinediones were synthesized as
and in Supplemental Materials. Moxifloxacin and ciprofloxacin were obtained from Bayer
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
377
described previously.19 Formation and detection of cleaved complexes was as described
378
previously6 and in Supplemental Materials. In all cases, a quinolone or dione was used to
379
form cleaved complexes.
380
Resealing of plasmid DNA was accomplished in two ways. In one, reaction mixtures,
381
prepared and incubated to obtain cleaved complexes, were incubated in EDTA at 37oC for 30
382
min before SDS (1% w/v) and proteinase K (100 µg ml-1) were added for an additional 15-
383
min incubation. In the other, aliquots of reaction mixtures, incubated as described for
384
complex formation, were incubated at various temperatures for 5 min followed by incubation
385
in 1% SDS and 100 µg ml-1 proteinase K for another 15 min at 37oC. In both reaction
386
schemes, EDTA concentration was brought to 50 mM prior to applying reaction mixtures to
387
agarose gels. Plasmid species were separated by gel electrophoresis and quantified.
388
For modeling studies, an initial, manual analysis and manipulation of
389
fluoroquinolone-gyrase cleaved complexes was performed using structures obtained from
390
PBD access numbers 2XKK for A. baumannii topoisomerase IV14 and 3LTN for S.
391
pneumoniae topoisomerase IV11 using WebLab ViewerLight. For computer-aided docking,
392
SYBYL-X 1.3 was used to prepare the 2XKK crystal structure for ligand docking.28
393
Standard Tripos procedures were followed for SYBYL-X 1.3 (Certara, L.P.). Briefly, metal
394
bonds were removed, atom types in the ligands were fixed, missing side chains were added,
395
protein termini were charged, hydrogen atoms were added, and a staged minimization of the
396
entire complex was performed. Details are provided in Supplementary Materials. The
397
quinazoline-2,4-dione ligands were docked in two steps. In the first step, dione UING5-157,
398
the cognate of moxifloxacin, was docked according to the procedure in Supplementary
399
Materials except that the magnesium ion of the magnesium-water bridge was removed prior
400
to docking. After docking, the top 20 binding poses were examined, and the highest scoring
401
pose that showed a hydrogen bond interaction between the dione C-2 carbonyl and ParC-
ACS Paragon Plus Environment
Page 16 of 33
Page 17 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
402
Arg123 was used as the template for subsequent docking of UING5-157 and UING5-207.
403
The parameters of the second docking run were identical to the first, except that deviation
404
from the ParC-Arg123 hydrogen-bond-forming binding pose template was required to exceed
405
5 pKd/Å2 to be scored. This very small "penalty" had the effect of fixing the dione core in
406
the position revealed by the 3LTN crystal structure11 while allowing the C-7 substituents to
407
sample various binding interactions with GyrB and DNA. Binding poses were examined and
408
visualized using the SYBYL-X 1.3 software.
409 410
SUPPLEMENTARY INFORMATION
411
Supporting tables and figures plus detailed descriptions of methods. This information is
412
available free of charge via Internet at http://pubs.acs.org
413
AUTHOR INFORMATION
414
Corresponding authors
415
*Email: :
[email protected];
[email protected];
[email protected] 416
417
Note:
418
The authors declare no competing financial interest.
419
ACKNOWLEDGEMENTS
420
We thank members of the Berger laboratory, especially K. Jude, for technical advice, M.
421
Malik for preparing figures, and the following for many experimental suggestions and critical
422
comments on the manuscript: M. Gennaro, K. Jude, M. Malik, R. Pine, and X. Zhao. KD
423
was a Visiting Scholar, University of California, Berkeley, CA.
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
424
425
FUNDING
426
This work was supported by the National Institutes of Health [R01AI073491 to K.D.,
427
R01AI87671 to R.K., R01CA077373 to J.B.]. Funding for open access charge: National
428
Institutes of Health.
429
430
REFERENCES
431
[1] Osheroff, N., and Zechiedrich, E. (1987) Calcium-promoted DNA cleavage by eukaryotic
432
topoisomerase II: trapping the covalent enzyme-DNA complex in an active form.,
433
Biochemistry 26, 4303-4309.
434
[2] Howard, M. T., Neece, S. H., Matson, S. W., and Kreuzer, K. N. (1994) Disruption of a
435
topoisomerase-DNA cleavage complex by a DNA helicase, Proc. Natl. Acad. Sci.
436
U.S.A. 91, 12031-12035.
437 438 439 440
[3] Snyder, M., and Drlica, K. (1979) DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid., J. Mol. Biol. 131, 287-302. [4] Drlica, K., Malik, M., Kerns, R. J., and Zhao, X. (2008) Quinolone-mediated bacterial death, Antimicrob Agents Chemother 52, 385-392.
441
[5] Kreuzer, K. N., and Cozzarelli, N. R. (1979) Escherichia coli mutants thermosensitive for
442
deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication,
443
transcription, and bacteriophage growth, J. Bacteriol. 140, 424-435.
444
[6] Mustaev, A., Malik, M., Zhao, X., Kurepina, N., Luan, G., Oppegard, L., Hiasa, H.,
445
Marks, K., Kerns, R., Berger, J., and Drlica, K. (2014) Fluoroquinolone-gyrase-DNA
446
complexes: two modes of drug binding, J Biol Chem 289, 12300-12312.
ACS Paragon Plus Environment
Page 18 of 33
Page 19 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
447
ACS Chemical Biology
[7] Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T., and Tomizawa, J.-L. (1977) Nalidixic
448
acid resistance: a second genetic character involved in DNA gyrase activity., Proc.
449
Natl. Acad. Sci. U.S.A. 74, 4772-4776.
450
[8] Sugino, A., Peebles, C., Kruezer, K., and Cozzarelli, N. (1977) Mechanism of action of
451
nalidixic acid: purification of Escherichia coli nalA gene product and its relationship
452
to DNA gyrase and a novel nicking-closing enzyme., Proc. Natl. Acad. Sci. U.S.A. 74,
453
4767-4771.
454
[9] Aldred, K., McPherson, S., Turnbough, C., Kerns, R., and Osheroff, N. (2013)
455
Topoisomerase IV-quinolone interactions are mediated through a water-metal ion
456
bridge: mechanistic basis of quinolone resistance, Nucleic Acids Res. 41, 4628-4639.
457
[10] Pan, X., Dias, M., Palumbo, M., and Fisher, L. (2008) Clerocidin selectively modifies
458
the gyrase-DNA gate to induce irreversible and reversible DNA damage., Nucleic
459
Acids Res. 36, 5516-5529.
460
[11] Laponogov, I., Pan, X., Veselkov, D., McAuley, K., Fisher, L., and Sanderson, M.
461
(2010) Structural basis of gate-DNA breakage and resealing by type II
462
topoisomerases, PLoS One 5, e11338.
463
[12] Laponogov, I., Sohi, M., Veselkov, D., Pan, X., Sawhney, R., Thompson, A., McAuley,
464
K., Fisher, L., and Sanderson, M. (2009) Structural insight into the quinolone-DNA
465
cleavage complex of type IIA topoisomerases., Nat Struct Mol Biol. 16, 667-669.
466
[13] Bax, B., Chan, P., Eggleston, D., Fosberry, A., Gentry, D., Gorrec, F., Giordano, I.,
467
Hann, M., Hennessy, A., Hibbs, M., Huang, J., Jones, E., Jones, J., Brown, K., Lewis,
468
C., May, E., Saunders, M., Singh, O., Spitzfaden, C., Shen, C., Shillings, A.,
469
Theobald, A., Wohlkonig, A., Pearson, N., and Gwynn, M. (2010) Type IIA
470
topoisomerase inhibition by a new class of antibacterial agents., Nature 466, 935-940.
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
471
[14] Wohlkonig, A., Chan, P., Fosberry, A., Homes, P., Huang, J., Kranz, M., Leydon, V.,
472
Miles, T., Pearson, N., Perera, R., Shillings, A., Gwynn, M., and Bax, B. (2010)
473
Structural basis of quinolone inhibition of type IIA topoisomerases and target-
474
mediated resistance. , Nat Struct Mol Biol. 17, 1152-1153.
475 476 477
[15] Deweese, J., and Osheroff, N. (2010) The use of divalent metal ions by type II topoisomerases., Metallomics 2, 450-459. [16] Aldred, K., McPherson, S., Wang, P., Kerns, R., Graves, D., Turnbough, C., and
478
Osheroff, N. (2012) Drug interactions with Bacillus anthracis topoisomerase IV:
479
biochemical basis for quinolone action and resistance., Biochemistry 51, 370-381.
480
[17] Pan, X., Gould, K., and Fisher, L. M. (2009) Probing the differential interactions of
481
quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV.,
482
Antimicrob Agents Chemother 53, 3822-3831.
483
[18] Aldred, K., Schwanz, H., Li, G., McPherson, S., CL Turnbough, J., Kerns, R., and
484
Osheroff, N. (2013) Overcoming target-mediated quinolone resistance in
485
topoisomerase IV by introducing metal ion-independent drug-enzyme interactions:
486
implications for drug design, ACS Chem Biol 8, 2660-2668.
487
[19] German, N., Malik, M., Rosen, J., Drlica, K., and Kerns, R. (2008) Use of gyrase
488
resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones,
489
Antimicrob Agents Chemother 52, 3915-3921.
490
[20] Malik, M., Marks, K., Mustaev, A., Zhao, X., Chavda, K., Kerns, R., and Drlica, K.
491
(2011) Fluoroquinolone and quinazolinedione activities against wild-type and gyrase
492
mutant strains of Mycobacterium smegmatis, Antimicrob Agents Chemother 55, 2335-
493
2343.
ACS Paragon Plus Environment
Page 20 of 33
Page 21 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
494
ACS Chemical Biology
[21] Oppegard, L. M., Streck, K., Rosen, J., Shwanz, H. A., Drlica, K., Kerns, R. J., and
495
Hiasa, H. (2010) Comparison of in vitro activities of fluoroquinolone-like 2,4- and
496
1.3-diones., Antimicrob Agents Chemother 54, 3011-3014.
497
[22] Noble, C., and Maxwell, A. (2002) The role of GyrB in the DNA cleavage-religation
498
reaction of DNA gyrase: a proposed two metal-ion mechanism., J. Mol. Biol. 318,
499
361-371.
500
[23] Pitts, S., Liou, G., Mitchenall, L., Burgin, A., Maxwell, A., Neuman, K., and Osheroff,
501
N. (2011) Use of divalent metal ions in the DNA cleavage reaction of topoisomerase
502
IV., Nucleic Acids Res. 39, 4808-4817.
503 504 505
[24] Sander, M., and Hsieh, T. (1983) Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster, J. Biol. Chem. 258, 8421-8428. [25] Maruri, F., Sterling, T., Kaiga, A., Blackman, A., vanderHeijden, Y., Mayer, C.,
506
Cambau, E., and Aubry, A. (2012) A systematic review of gyrase mutations
507
associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed
508
gyrase numbering system, J Antimicrob Chemother 67, 819-831.
509
[26] Wu, C., Li, T., Farh, L., Lin, L., Lin, T., Yu, Y., Yen, T., Chiang, C., and Chan, N.
510
(2011) Structural basis of type II topoisomerase inhibition by the anticancer drug
511
etoposide. , Science 333, 459-462.
512
[27] Schoeffler, A., May, A., and Berger, J. (2010) A domain insertion in Escherichia coli
513
GyrB adopts a novel fold that plays a critical role in gyrase function, Nucleic Acids
514
Res. 38, 7830-7844.
515 516
[28] Jain, A. (2003) Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , J Med Chem 46, 499-511.
517
518
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
519
FIGURE LEGENDS
520
Figure 1. Structure and activity differences between quinolones and diones. A. Compounds
521
used in the present work. Structures of the C-7 substituents (R1) are above the dashed line as
522
a-f. Below the dashed line are fluoroquinolones (left) and quinazolinediones (right).. The
523
report focuses on the 3-(aminomethyl)pyrrolidinyl C-7 group (boxed). B. Formation of
524
cleaved complexes occurs at lower concentrations of fluoroquinolone (empty bars) than
525
quinazolinedione (filled bars). Cleaved complex formation was assayed as in Methods to
526
determine the concentration of quinolone or dione required to linearize 20% of the plasmid
527
DNA. Error bars represent standard deviation for independent experiments.
528
Figure 2. EDTA-mediated resealing of DNA in cleaved complexes formed with quinolone
529
and dione. Incubations containing gyrase, DNA, and either fluoroquinolone (UING5-249 at
530
2 µM, empty circles) or dione (UING5-207 at 20 µM, filled circles) generated similar
531
amounts of cleaved complexes for both compounds. Parallel reaction mixtures were
532
incubated at the indicated concentration of EDTA for an additional 30 min before treatment
533
with SDS and proteinase K. The fraction of total DNA in linear (Panel A) or nicked (Panel B)
534
forms was determined by gel electrophoresis. Data were normalized to a zero-EDTA control,
535
which was similar for quinolone and dione. Replicate experiments gave similar results; error
536
bars indicate standard deviation.
537
Figure 3. Thermal reversal of cleaved complexes formed with quinolones and diones. A.
538
Comparison of quinolones and cognate diones. Cleaved complexes were formed as
539
described in Methods and then incubated at various temperatures to determine the
540
temperature causing 50% resealing of DNA. B. Relationship between drug concentration
541
required for complex formation and thermal resealing of DNA. Concentrations of
542
fluoroquinolone (empty circles) or quinazolinedione (filled circles) required to trap 20% of
ACS Paragon Plus Environment
Page 22 of 33
Page 23 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
543
the plasmid DNA in a linear form were determined as in Figure 1B, and temperatures at
544
which 50% of the linear DNA was resealed were determined. Letters indicate paired
545
fluoroquinolones and diones (a = UING5-249/207; b = moxifloxacin/UING5-157; c =
546
UING5-248/159; d = PD161148/UING5-209); cip, ciprofloxacin; gat, gatifloxacin. Error
547
bars indicate standard deviation of means.
548
Figure 4. Effect of GyrA-G81C gyrase on dione and quinolone activity. A. Compound
549
concentration effects on complex formation. Panel i. Wild-type gyase. Panel ii. GyrA-G81C
550
gyrase. Symbols: empty circles, fluoroquinolone UING5-249; filled circles, dione UING5-
551
207. Similar results were obtained with four replicate experiments. B. DNA resealing
552
stimulated by EDTA. Reaction mixtures containing cleaved complex were treated with the
553
indicated concentrations of EDTA and analyzed as in Figure 2. Linear DNA was quantified
554
and expressed as a percent of the zero-EDTA control. Symbols: filled circles, dione UING5-
555
207 at 80 µM; empty circles, fluoroquinolone UING5-249 at 40 µM. Similar results were
556
obtained with three independent replicate experiments. C. DNA resealing stimulated by high
557
temperature. Reaction mixtures containing cleaved complexes were treated and analyzed as
558
in Figure 3. Panel i. Complexes formed with fluoroquinolone UING5-249. Panel ii.
559
Complexes formed with dione UING5-207. Symbols; empty symbols wild-type gyrase;
560
filled symbols GyrA81C gyrase. Similar results were obtained with four replicate
561
experiments.
562
Figure 5. Location of C-7 ring substitutents relative to amino acid 466 of GyrB in cleaved
563
complexes. A potential salt bridge and hydrogen bond between the C-7 ring systems and
564
GyrB-466E are shown. Panel A. Dione binding. The C-7 ring system of UING5-157 is
565
shown in light gray, while that of UING5-207 is in dark gray. Panel B. Quinolone binding.
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
566
The C-7 ring system of moxifloxacin is shown in light gray, while that of UING5-249 is in
567
dark gray.
568
Figure. 6. Docking of quinolones and diones with wild-type enzyme. Representative
569
cleaved-complex interactions were taken from the top 20 binding poses obtained from
570
docking moxifloxacin (A), UING5-249 (B), UING5-157 (C), and UING5-207 (D) into the
571
2XKK (wild-type) crystal structure. Hydrogen bonds are shown as dashed yellow lines. The
572
top scoring and most consistent pose for moxifloxacin and UING5-157 show a hydrogen
573
bond to the deoxyribose oxygen of dA-20; top pose of UING5-249 and UING5-207 show
574
hydrogen bonds from the C-7 amine to E437 and R418. Both diones were anchored to ParC-
575
Arg123 through a hydrogen bond with their C-2 carbonyl group.
576
Figure 7. Docking of quinolones and diones with ParE/GyrB mutant enzyme. Representative
577
ternary complex interactions were taken from the top 20 binding poses obtained from
578
docking moxifloxacin (A), UING5-249 (B, C), UING5-157 (D), and UING5-207 (E) into the
579
2XKK crystal structure modified from ParE-Glu437 to Cys437. Hydrogen bonds are shown
580
as dashed yellow lines. The top pose for moxifloxacin (A) showed formation of the same
581
hydrogen bond to dA-20 as found with the wild-type structure. However, when UING5-249
582
was docked into the E437C mutant structure (B, C), the top scoring poses no longer showed
583
hydrogen bonds to the 437 position or to R418. Instead, the C-7 amine rotated about 180
584
degrees to form hydrogen bond interactions with DNA (dA-20 or dT-19). In the case of
585
docking UING5-157 (D) into the mutant enzyme, the top two poses (shown) either form a
586
hydrogen bond to R418 or form no electrostatic/hydrogen bond interaction. When UING5-
587
207 (E) was docked, its top pose displayed hydrogen bonds from the C-7 amine to both the
588
R418 side chain and to the deoxyribose oxygen of dG-17.
ACS Paragon Plus Environment
Page 24 of 33
Page 25 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
589
Figure 8. C-7 ring substituent affects GyrB-466C-mediated reduction in complex-forming
590
activity. Cleaved complexes were formed at the indicated concentrations of fluoroquinolone
591
or dione. Percent linear DNA was determined by gel electrophoresis. Panel A, dione
592
UING5-207; Panel B, dione UING5-157; Panel C, fluoroquinolone UING5-249; Panel D,
593
moxifloxacin. Symbols: empty circles (wild-type gyrase), filled circles (GyrB-466C gyrase).
594
Panel E. Comparision of cleavage activities. Compound concentration required to achieve
595
20% linear DNA for GyrB-466C gyrase was divided by that value for wild-type gyrase,
596
determined for each test compound (average values from multiple experiments; error bars
597
represent standard deviation). Arrows indicate 20% linear DNA.
598
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
134x89mm (300 x 300 DPI)
ACS Paragon Plus Environment
Page 26 of 33
Page 27 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
141x321mm (600 x 600 DPI)
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
157x376mm (600 x 600 DPI)
ACS Paragon Plus Environment
Page 28 of 33
Page 29 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
140x106mm (300 x 300 DPI)
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
93x63mm (300 x 300 DPI)
ACS Paragon Plus Environment
Page 30 of 33
Page 31 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
140x115mm (300 x 300 DPI)
ACS Paragon Plus Environment
ACS Chemical Biology
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
140x115mm (300 x 300 DPI)
ACS Paragon Plus Environment
Page 32 of 33
Page 33 of 33
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
ACS Chemical Biology
58x158mm (300 x 300 DPI)
ACS Paragon Plus Environment